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Cyclosporine microemulsion increases drug exposure and re-
duces acute rejection without incremental toxicity in de novo renal
transplantation.
Background. The new oral microemulsion formulation of cyclo-
sporine (Neoral®) possesses superior pharmacokinetics to the
conventional formulation, Sandimmun® (SIM), providing more
complete and predictable absorption, and less pharmacokinetic
variability.
Methods. The safety and tolerability of Neoral®, together with
the incidence of acute rejection episodes and graft survival, were
compared to the conventional cyclosporine formulation, SIM, in a
prospective, randomized, double-blind multicenter trial. A total of
167 patients who received a first or second cadaveric renal
transplant in 21 participating centers in six countries were ran-
domized equally to two treatment groups and followed for three
months after transplantation. Outcomes were analyzed across
treatment, center and regional groups. In addition, a nested
pharmacokinetic study was performed in four of these centers
throughout the period of follow-up.
Results. No difference was detected between the safety or
tolerability of the two formulations. Kidney function and other
laboratory parameters remained comparable in Neoral®- and
SIM-treated patients throughout the study. However, the number
of patients experiencing acute rejection was significantly reduced
for the Neoral group (44.2% vs. 60.5%; P 5 0.044), and signifi-
cantly fewer patients experienced multiple episodes of rejection
(12.8% vs. 22.2%, P 5 0.028). The proportion of patients free of
rejection at three months was significantly higher in patients
treated with Neoral® than in those receiving SIM (Kaplan-Meier
estimated probability of remaining rejection-free at 3 months 5
55% for the Neoral® group, compared with 39% for the SIM
group, P 5 0.046, log rank test). Similar results were obtained
when acute rejection, graft loss and death were used as a
combined endpoint (Kaplan-Meier estimated probability for
Neoral® group 5 54%, compared with 38% for the SIM group,
P 5 0.047, log rank test). Comparison of results by center or
regional groups did not show any significant treatment interac-
tion. A nested pharmacokinetic evaluation (four centers; 28
subjects) showed that the bioavailability of cyclosporine from
Neoral® was significantly higher than from SIM at all assessment
times. Specifically, at weeks 2, 4 to 6, and 12, dose-normalized
AUC was 49%, 63% and 32% higher for Neoral®. Dose-normal-
ized peak cyclosporine blood concentrations and AUC stabilized
by weeks 4 to 6 in patients receiving Neoral®, whereas these
values increased slowly in SIM-treated patients without reaching
the levels achieved in the Neoral® group.
Conclusions. These results suggest that the superior pharmaco-
kinetic characteristics of the microemulsion formulation of cyclo-
sporine lead to more efficient immunosuppression during the first
critical months after transplantation, without a deleterious impact
on clinical safety.
Cyclosporine is the principal immunosuppressant cur-
rently used to prevent graft rejection, but its clinical use is
complicated by highly variable pharmacokinetic charac-
teristics [1, 2]. A new oral formulation of cyclosporine
has been developed using microemulsion technology
(Neoral®). Pharmacokinetic studies in healthy subjects and
renal transplant recipients have shown that this formulation
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possesses superior pharmacokinetic characteristics, with
more complete and predictable absorption of the drug from
the gastrointestinal tract, resulting in less pharmacokinetic
variability [3, 4].
The safety and tolerability of this microemulsion formu-
lation, together with the incidence of acute rejection epi-
sodes and graft survival, were compared to the conven-
tional cyclosporine formulation, Sandimmun® (SIM), in an
international multicenter study in new renal transplant
recipients. The study design, execution and targeted patient
population were identical for all 21 study centers in the six
participating countries. In addition, a nested pharmacoki-
netic study was performed in four of these centers through-
out the period of follow-up.
METHODS
Study design
This prospective, randomized, double blind, concentra-
tion-controlled multicenter study compared the safety and
tolerability of Neoral® and SIM in new renal transplant
recipients. The null hypothesis presumed no difference in
outcome between the two formulations, which both contain
the same active molecule. Twelve centers in five European
countries (Austria, Belgium, Germany, Switzerland and the
UK) and nine centers in Canada participated in the trial.
The study was performed in accordance with the Declara-
tion of Helsinki and the principles of Good Clinical Prac-
tice.
Patients
Patients receiving their first or second renal cadaveric
allograft were eligible for this study. After written informed
consent was obtained, patients were randomized to receive
either Neoral® (N 5 86) or SIM (N 5 81) as a component
of the established immunosuppressive protocol at that
center. All patients who received at least one dose of study
medication were included in the analysis, following the
principle of intention to treat.
Immunosuppressive therapy
Immunosuppression was standardized within each center
as “best local therapy,” and was identical across both
treatment groups. Cyclosporine treatment was concentra-
tion-controlled, and the therapeutic target range for trough
(pre-dose) whole blood concentrations adopted for optimal
clinical care by each participating center throughout the
treatment course was defined prior to study commence-
ment. Patients were randomized to receive either SIM or
Neoral® as soon as oral treatment was started. Identical-
looking soft gelatin capsules of Neoral® (Novartis Pharma
AG, Basel, Switzerland) and commercial Sandimmun®
(Novartis Pharma AG, Basel, Switzerland) were provided
in three capsule strengths (25 mg, 50 mg and 100 mg) and
were administered according to individual dosage require-
ments. Use of induction therapy with antilymphocyte anti-
bodies or intravenous SIM was allowed according to the
protocol of each center. Target cyclosporine trough levels
were individually defined for each patient and for every
visit. Dosages of the study drugs were adjusted to maintain
the trough levels within the predefined therapeutic range,
which was modified only in cases of clinical evidence of
under- or over-exposure. Drugs known to influence cyclo-
sporine pharmacokinetics or to increase its toxicity were
not allowed during the study.
Outcome measures
Patients were followed for the first three months post-
transplant in order to encompass the period of greatest
rejection risk. Outcome measures included adverse events,
graft function and the incidence of acute rejection episodes.
Adverse events were recorded as reported by the patients,
who were also examined for known cyclosporine-related
side effects at each visit. Renal function was monitored by
serum creatinine concentrations and by 24-hour measured
creatinine clearance at each scheduled visit. Blood pres-
sure, temperature and pulse rate were recorded and blood
was collected in order to determine hematologic [red blood
cell (RBC), white blood cell (WBC), differential blood
count, platelets] and biochemical (urea, uric acid, liver
enzymes, bilirubin, protein, electrolytes, lipids, glucose)
safety parameters.
Details of all episodes of acute graft rejection, including
clinical severity, biopsy results, dosages of study medica-
tion, creatinine levels, cyclosporine trough levels and treat-
ment were collected. Acute rejection episodes were defined
according to clinical criteria, response to treatment and
results of the histological assessment.
Cyclosporine measurement
Whole blood samples were collected for measurement of
trough cyclosporine levels on each patient at each study
visit. Measurement was performed at each center using
local methodology to permit dosage adjustments accord-
ing to clinical need. The same samples were also mea-
sured at a central laboratory using the commercially
available Sandimmun® radioimmunoassay kit (Novartis
Pharma AG), which employs a monoclonal antibody spe-
cific for cyclosporine [5]. All analyses comparing trough
levels between treatment arms were performed using the
values measured at the central laboratory. In addition,
complete 12-hour pharmacokinetic profiles were per-
formed at week 2, between weeks 4 and 6, and at week 12
in a nested subgroup of 21 patients in four Canadian
centers. Concentrations of cyclosporine for these analyses
were assayed at the central laboratory only. Pharmacoki-
netic parameters assessed included the time to maximum
cyclosporine concentration (tmax), maximum cyclosporine
concentration (Cmax) and area under the blood concen-
tration-time curve (AUC).
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Statistical methods
Patients were randomly assigned to treatment using a list
created for each center by Biomedical Operations, Novartis
Pharma AG, Basel, in a block size of four. Data were
analyzed using standard software.
Demographic characteristics at baseline, the incidence of
adverse events, the incidence and severity of known cyclo-
sporine side effects, changes in blood pressure, hemato-
logic and biochemical parameters were analyzed as appro-
priate using Fisher’s exact, Pearson’s Chi square and
Wilcoxon rank sum tests. Differences in pharmacokinetic
parameters were tested by an ANOVA for a parallel group
design with repeated measures within each subject.
Dosages of study medication and cyclosporine blood
levels were analyzed by fitting generalized linear models,
including terms for treatment, study, and treatment-by-
study and treatment-by-center group interaction.
Acute rejection episodes were analyzed using survival
analysis techniques. Kaplan-Meier estimates of the propor-
tion of patients without acute rejection episodes, without
graft loss and/or death were calculated and the correspond-
ing survival distribution functions were compared between
treatment arms using log rank and Wilcoxon tests. Time to
acute rejection or graft loss and treatment-risk factor
interactions were further analyzed by fitting Cox propor-
tional hazards models, including interaction terms for
center location and immunosuppressive protocol, and by
performing subgroup analysis.
To determine whether the immunosuppressive protocol
exerted an important influence on outcome, centers were
divided into three categories according to the drug combi-
nation employed: (a) centers using cyclosporine alone or in
combination with steroids; (b) centers using triple therapy
with cyclosporine, prednisone and azathioprine, and (c)
centers using quadruple therapy with induction antilym-
phocyte antibodies, cyclosporine, prednisone and azathio-
prine. All analyses were performed for the whole study
population, on data stratified by region (Europe, Western
Canada, and Eastern Canada), and by immunosuppressive
protocol. The level of significance was set to 0.05 in all
analyses.
RESULTS
Patient characteristics, recruitment and completion
A total of 167 renal transplant recipients (58 female and
109 male) with a mean age of 44.5 years (range 18 to 65
years) were enrolled into the study. Baseline patient char-
acteristics, number of prior transplants, co-morbid diabetes
mellitus and degree of HLA match did not differ signifi-
cantly between treatment groups (Table 1). Overall, 136 of
167 (81.4%) patients completed the three-month treatment
period: 71 (82.6%) of these were randomized to receive
Neoral® and 65 (80.2%) to receive SIM. There were no
differences in the incidence of, or reasons for, premature
withdrawal between the two treatment arms.
Immunosuppressive therapy
The immunosuppressive regimen was comparable in the
two study groups. A total of 36 patients (21.6%) received
induction therapy with antilymphocyte antibodies; 86 pa-
tients (51.5%) received triple therapy with cyclosporine,
azathioprine and steroids, while 45 patients (26.9%) re-
ceived cyclosporine alone or in combination with steroids.
Intravenous cyclosporine was employed in 62.3% of pa-
tients.
When comparing the Neoral® and SIM groups, the mean
doses of prednisone (2.0 vs. 1.9 mg/kg/day) and azathio-
prine (1.8 vs. 1.7 mg/kg/day) were almost identical in the
two groups at the commencement of the trial. Study
medication was decreased more rapidly in the Neoral®
group, reflecting the superior absorption from this formu-
lation, and the difference between treatment arms reached
statistical significance at week 4 (P 5 0.026). By week 12,
the mean daily dose of Neoral® was 4.5 6 1.9 mg/kg/day,
approximately 8% lower than the mean daily dose of SIM
(4.9 6 1.9 mg/kg/day) although this difference was no
longer significant (Table 2). There was no significant dif-
ference in the doses of azathioprine or steroids between the
two treatment groups at any time within the study.
Pharmacokinetics
The mean cyclosporine trough levels did not differ
significantly between the treatment arms at any time
throughout the study (Table 2). At 12 weeks, the mean
whole blood trough level was 208 6 146 ng/ml in the
Neoral® group and 188 6 106 ng/ml in the SIM group (P 5
0.57). In contrast, exposure to cyclosporine throughout the
dosing interval was significantly increased in the group
receiving Neoral® (Table 3). Dose-normalized peak and
area under the time-concentration curve (AUC) increased
between week 2 and weeks 4 to 6 in patients receiving
Neoral® and then remained stable. In contrast, these
parameters increased for SIM throughout the 12 weeks of
follow-up, without either reaching a plateau or achieving
the levels in the Neoral® group. Between-formulation
Table 1. Demographic characteristics of transplant patients by
treatment group
Neoralt
(N 5 86)
SIM
(N 5 81) P value
Age years 44.1 6 13.1 45.4 6 13.3 0.281
Sex (male/female) 60/26 49/32 0.220
Height 170 6 8 168 6 11 0.380
Weight 71 6 13 71 6 14 0.840
Diabetes mellitus 9 (10.5%) 5 (6.2%) 0.415
First transplant 77 (89.5%) 78 (96.3%) 0.092
HLA mismatch 0-2 32 (37.2%) 27 (33.4%) 0.610
HLA mismatch 3-6 54 (62.7%) 54 (66.7%)
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comparisons indicated that the rate and extent of cyclo-
sporine absorption from Neoral® were significantly higher
than from SIM over the study duration. Dose-normalized
AUC was 49%, 63% and 32% higher for Neoral® than for
SIM at weeks 2, 4 to 6 and 12, respectively.
Acute rejection
The incidence of acute graft rejection was significantly
decreased in the Neoral® treatment group. Thirty-eight out
of 86 (44.2%) patients experienced an episode of acute
rejection compared with 49/81 (60.5%) receiving SIM (P 5
0.044), an observation consistent in both European and
Canadian arms of the trial when stratified by study site (P 5
0.038). In addition, only 11 of 86 (12.8%) patients in the
Neoral® group experienced more than one rejection epi-
sode compared with 18 of 81 (22.2%) in the SIM group
(P 5 0.028) (Table 4). The Kaplan-Meier estimated prob-
ability of remaining free of rejection throughout the period
of follow-up was significantly higher in the Neoral® group
(55%) than in the SIM group (39%; P 5 0.046; Fig. 1).
Analysis using the Cox proportional hazards model re-
vealed that only age had a significant impact on the
incidence of acute rejection. Patients more than 50 years of
age who were treated with Neoral® had a significantly
lower risk of acute rejection than those treated with SIM
[relative risk, RR 5 0.450, 95% confidence intervals (CI)
0.222 to 0.911, P 5 0.027]. The risk ratio was also reduced
for female patients, but did not reach statistical significance
(RR 5 0.54, CI 5 0.258–1.114, P 5 0.095).
There were no differences in graft loss and patient death
between the two treatment groups (SIM, 0.909; Neoral®,
0.914; P 5 0.87, log rank test). Eight patients out of 86
(9.3%) in the Neoral® group lost their graft, compared with
7 of 81 (8.6%) in the SIM group (P 5 0.90). Two patients
died as a result of sepsis, one in each treatment group.
When acute rejection, graft loss and death were used as a
combined endpoint, outcome remained significantly supe-
rior in the group receiving Neoral® (Kaplan-Meier esti-
mated probability for Neoral® group 5 54%, compared
with 38% for the SIM group, P 5 0.047, log rank test).
Influence of immunosuppressive protocol
The incidence of acute rejection was significantly lower
in the Neoral® group when stratified by both study location
(P 5 0.038) and immunosuppressive protocol (P 5 0.035),
although there was a marginally significant effect of the
immunosuppressive protocol employed (P 5 0.065). The
incidence of acute rejection was lower in patients receiving
Neoral® than SIM in all three groups when centers were
divided according to immunosuppressive protocol, al-
though individual differences did not reach statistical sig-
nificance due to the small group size. Patients in centers
Table 2. Mean (6SD) dosage of study medication and cyclosporine levels by treatment group
Treatment group Week 1 Week 4 Week 8 Week 12
Neoralt
Cyclosporine mg/kg/day 7.2 6 4.6 6.0 6 3.2 5.1 6 2.2 4.5 6 1.9
CsA level ng/ml 229 6 165 233 6 136 227 6 148 208 6 146
Sandimmunt
Cyclosporine mg/kg/day 6.6 6 3.9 7.0 6 3.7 5.5 6 2.0 4.9 6 1.9
CsA level ng/ml 194 6 117 237 6 143 193 6 109 188 6 106
Table 3. Pharmacokinetic parameters for cyclosporine (Neoralt vs SIM) at different timepoints after transplantation
Week 2 Weeks 4–6 Week 12
P valueNeoralt SIM Neoralt SIM Neoralt SIM
Dose mg/day 614 6 207 658 6 184 481 6 154 485 6 155 358 6 135 315 6 88 $ 0.25
Cmin,b ng/ml 239 6 86 246 6 83 227 6 75 179 6 83 194 6 158 137 6 56 $ 0.25
tmax hr 1.7 6 0.5 2.9 6 2.2 2.3 6 0.8 3.3 6 2.8 1.7 6 0.6 4.5 6 2.7 , 0.01
AUCt,b ng z hr/ml 7156 6 2275 5221 6 1657 6868 6 2121 4493 6 1716 5006 6 1630 3407 6 1065 —
Cmax,b ng/ml 1435 6 532 988 6 359 1432 6 396 922 6 408 1102 6 438 728 6 366 —
Cmax,b/dose ng/ml/mg 5.0 6 2.2 3.0 6 0.9 6.2 6 1.3 3.9 6 1.9 6.2 6 2.0 4.7 6 2.1 , 0.01
AUCt,b/dose
ng z hr/ml/mg
24.4 6 7.4 16.3 6 4.8 29.0 6 4.9 18.7 6 7.0 28.4 6 5.0 21.8 6 5.2 , 0.01
Abbreviations are: Cmin,b, minimal blood concentration at the end of the dosing interval; Cmax,b, maximal blood concentration; AUCt,b, area under
the blood concentration curve, over one dosing interval; tmax, time to reach maximum measured drug concentration.
Table 4. Incidence and frequency of acute rejection
Neoralt
(N 5 86)
SIM
(N 5 81)
P value
(between
treatments)
Number of patients 38 (44.2%) 49 (60.5%) 0.044a
experiencing rejections 0.038b
Number of patients 11 (12.8%) 18 (22.2%) 0.028a
experiencing more
than 1 rejection
0.031b
a Unstratified P value from Pearson Chi square test
b P value from Pearson Chi square test stratified by study site
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using cyclosporine alone or with steroids showed the high-
est incidence of acute rejection episodes in both SIM (14 of
21, 66.7%) and Neoral® (13 of 24, 54.2%) groups, with a
12.5% risk reduction due to Neoral® (P 5 0.5). The
incidence of acute rejection episodes was lower among
patients in centers using triple therapy with cyclosporine,
azathioprine and steroids (SIM, 25 of 41, 61.0%; Neoral®,
21 of 45, 46.7%), and the risk reduction due to Neoral®
(14.3%) was superior, though not significantly so (P 5
0.202). The lowest incidence of rejection was seen among
patients in centers using quadruple therapy with induction
antilymphocyte antibodies in combination with cyclospor-
ine, azathioprine and steroids. Only 4 of 17 (23.5%) of
these patients in the Neoral® group experienced an acute
rejection episode compared with 10 of 19 (52.6%) in the
SIM group (P 5 0.097), a risk reduction of 29.1%.
Safety and tolerability
Kidney function. Median serum creatinine fell more
quickly after transplantation in the Neoral® group and was
comparable to, or lower than, that in the SIM group at all
time points throughout the study period (Fig. 2). The
difference in median serum creatinine was statistically
significant three weeks after transplantation (Neoral®,
141.4 mmol/liter; SIM, 176.8 mmol/liter; P 5 0.021), al-
though this was not sustained. Measured creatinine clear-
ance showed the same trend, but there was no significant
difference between the two treatment arms.
Adverse effects. Eighty-two patients receiving Neoral®
(95.3%) reported at least one adverse event during the
study compared with 80 (98.8%) receiving SIM (P 5 0.369).
There was no difference in the type of adverse events
reported, or in the incidence of those events related to
cyclosporine (Table 5). The number of patients experienc-
ing one or more serious adverse events was lower in the
Neoral® group, 46 (53.5%), compared with 55 (67.9%) in
the SIM group (P 5 0.060). One malignancy (adenocarci-
noma of the prostate) was diagnosed in a patient in the SIM
group during the study. Infections were reported as serious
adverse events in 11 of 86 patients (12.8%) in the Neoral®
group and 11 of 81 patients (13.6%) in the SIM group.
There were no clinically relevant differences between the
two study groups in any of the other laboratory safety
parameters, including urea, uric acid, bilirubin, serum
glutamate oxaloacetate transaminase, serum glutamate
pyruvate transaminase, alkaline phosphatase, electrolytes,
cholesterol, triglycerides, glucose and hematologic param-
eters. No differences were observed in systolic or diastolic
blood pressure.
DISCUSSION
Inadequate absorption and unpredictable pharmacoki-
netic variability remain the most important limitations to
effective treatment with SIM. Previous reports have dem-
onstrated a high correlation between these factors and
acute rejection in both renal [6] and non-renal graft
recipients [7]. Moreover, acute rejection appears to be an
important factor in the occurrence of subsequent chronic
rejection [8, 9]. Thus, an oral formulation of cyclosporine
that ensures more complete and consistent absorption may
have beneficial acute and long-term effects.
Fig. 1. Probability of remaining free from rejection during the first three
months post-transplantation. The solid line is the Neoral® group and the
dashed line is the Sandimmun® (SIM) group; P 5 0.046 by the log rank test.
Fig. 2. Median serum creatinine levels following transplantation (mmol/
liter). Box and whisker plot: boxes indicate upper and lower quartiles;
whiskers extend over 1.5 times the interquartile range. Symbols are: (f)
Neoral®; (M) Sandimmun® (SIM).
Table 5. Incidence of adverse events typical for cyclosporine after three
months of treatment
Adverse reaction
Neoralt
N (%)
SIM
N (%)
P valuea
(between
treatments)
Gingival hyperplasia 12 (14.0) 22 (27.2) 0.038
Hypertrichosis 51 (59.3) 54 (66.7) 0.558
Edema 26 (30.2) 31 (38.3) 0.436
Tremor 44 (51.2) 49 (60.5) 0.248
Nausea, vomiting,
gastric pain
24 (27.9) 27 (33.3) 0.990
Headache 17 (19.7) 26 (32.1) 0.368
Paresthesia 25 (29.1) 20 (24.7) 0.450
a P value from Wilcoxon rank sum test
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This study was performed to evaluate the impact of the
superior absorption of cyclosporine from Neoral® in terms
of safety, tolerability and biological effect. The patient
population selected was representative of the adult renal
transplant population in the participating centers and there
were no significant demographic differences between either
the geographic populations or treatment arms. The treat-
ment protocols used in the study represented the best
clinical practice of the participating centers. Efficacy was
not the primary endpoint for which the study was powered,
but acute rejection episodes and graft survival were inves-
tigated as part of the safety evaluation.
Neoral® provided a significantly higher exposure to
cyclosporine than the equivalent dose of SIM throughout
the first three months after transplantation. Sequential
pharmacokinetic profiles performed in a nested subgroup
of patients demonstrated that pharmacokinetic stability was
achieved sooner with Neoral®, and that the dose-normal-
ized AUC remained unchanged between one and three
months post-transplant. This contrasted with patients re-
ceiving SIM, where dose-normalized exposure continued to
increase slowly over the 12-week study period. Between-
formulation comparisons indicated that the rate and extent
of cyclosporine absorption from Neoral® were significantly
higher over the study duration [10].
Despite higher drug exposure, Neoral® was as safe and
as well tolerated as SIM. There was no difference in the
safety of the two formulations in any parameter measured,
including those particularly related to cyclosporine. Kidney
function was not impaired but, in contrast, the serum
creatinine improved slightly more quickly in patients re-
ceiving Neoral®, perhaps reflecting a reduction in immu-
nologic injury to the graft. Although a similar trend was
observed in creatinine clearance, this did not reach statis-
tical significance. This was possibly related to the greater
variance of this measure.
The incidence of acute rejection was significantly re-
duced, by approximately 25%, in the Neoral® group and
fewer patients treated with Neoral® experienced multiple
rejections. Survival analysis showed that the proportion of
patients free of rejections at three months was significantly
higher in patients treated with Neoral® (Neoral® group 5
55%, compared with 39% for the SIM group; P 5 0.046, log
rank test). The results were the same when acute rejections,
graft loss or death were investigated as a combined end-
point, indicating that the reduction in rejection rate was
achieved without excessive immunosuppression and did not
increase the risk to life or graft function. Data analysis was
performed using tests stratified for center location and,
where appropriate, immunosuppressive protocols including
terms for study and treatment-by-study interaction. The
results of these analyses did not differ from those of the
unstratified tests and no significant treatment-by-center
group interaction was detected. The incidence of graft loss
and death was low in this study, and there were no
differences between treatment arms during the period of
follow-up.
The incidence of acute rejection observed in the SIM-
control population of this study was higher than that
normally anticipated in patients receiving cyclosporine. No
clear explanation for this was obtained from the analysis.
The incidence of rejection was comparable across all
geographic regions within the study, and did not appear to
reflect recruitment or selection bias. The treatment proto-
cols employed were determined as optimal therapy by each
center, and mean cyclosporine levels were within the
accepted range at all time points, arguing strongly against
inadequate cyclosporine treatment as the cause of height-
ened rejection activity. Acute rejection was most frequent
in those centers using cyclosporine alone or in combination
with prednisone, and there was a trend towards a lower
incidence of rejection in centers using triple or quadruple
immunosuppression with azathioprine or antilymphocyte
antibodies. The benefit of Neoral® was observed in all
treatment combinations, however, and conferred the great-
est protection in centers using quadruple therapy, where
the incidence of rejection was less than half that in the SIM
group (23.5% vs. 52.6%: P 5 0.097).
Including the current study, three pivotal multicenter
trials have been conducted to investigate the action of
Neoral® in de novo renal transplantation [11, 12]. The data
reported here show that the superior pharmacokinetic
characteristics of the microemulsion formulation allow
more rapid, complete and consistent absorption of cyclo-
sporine within the first twelve weeks after transplantation.
Cyclosporine exposure in the present study was increased
by 30 to 50%, exceeding that reported by Barone et al
during the same interval [13]. Formal pharmacokinetic
analysis was not planned in the multicenter study now in
progress in the United Kingdom; however, target therapeu-
tic cyclosporine levels were achieved more quickly and
remained higher with a lower administered dose in patients
receiving Neoral® [12]. Despite the substantial increase in
drug exposure, no incremental toxicity was observed in
patients receiving Neoral® in any of the three pivotal
studies so far conducted. No change in renal function has
been observed in the current study in patients who were
followed for up to 12 months [14], and recent data indicate
no increase in long-term toxicity in renal transplant patients
receiving Neoral® for over two years [15]. The lower
incidence of acute rejection in patients receiving Neoral®,
reported here, is consistent with data reported by Lindholm
and Kahan showing that superior outcome is closely related
to increased cyclosporine bioavailability [6]. Preliminary
analysis of the multicenter trial in the United Kingdom
demonstrates a similar reduction in both the incidence of
(46.4% vs. 31.9%; P 5 0.016) and treatment for acute
rejection (54.6% vs. 41.4%; P 5 0.03) in patients random-
ized to receive Neoral® [12]. However, a comparable
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reduction in rejection risk was not observed in the multi-
center study recently performed in the United States [11].
This apparent lack of effect may be explained by the
comparatively lower incremental cyclosporine exposure in
the Neoral® group within that particular trial. However, the
relationship between drug exposure and rejection risk in
patients receiving Neoral® remains to be determined by
appropriately powered pharmacokinetic studies now in
preparation.
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